Aldosterone Antagonism Improves Endothelial-Dependent Vasorelaxation in Heart Failure via Upregulation of Endothelial Nitric Oxide Synthase Production

Journal of Cardiac Failure

Volumn 12, Issue 3, 2006, Pages 240-245

  Thai, Hoang M ^a   Do, Bao Q ^a   Tran, Trung D ^a   Gaballa, Mohamed A ^a   Goldman, Steven ^a  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

Author keywords

Endothelial dependent vasorelaxation; nitric oxide; spironolactone

Indexed keywords

ACETYLCHOLINE; ALDOSTERONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G) METHYLARGININE; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; ENZYME SYNTHESIS; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE PRESSURE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; UPREGULATION; VASCULAR ENDOTHELIUM; VASODILATATION;

ALDOSTERONE ANTAGONISTS; ANIMALS; ENDOTHELIUM, VASCULAR; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; MALE; NITRIC OXIDE SYNTHASE; RATS; RATS, SPRAGUE-DAWLEY; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE; VASODILATION;

EID: 33646488692     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.01.002     Document Type: Article

References (46)

1. Swedberg K., Eneroth P., Kjekshus J., and Snapinn S. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure. Am J Cardiol 66 (1990) 40D-45D
2. Swedberg K., Eneroth P., Kjekshus J., and Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82 (1990) 1730-1736
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 319 (1988) 293-302
4. Cohn J., and Tognoni G. the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin receptor valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
5. Pitt B., Zannad F., Remme W., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
6. Struthers A.D. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J 16 (1995) N103-N106
7. Davis K.L., and Nappi J.M. The cardiovascular effects of eplerenone, a selective aldosterone receptor antagonist. Clin Ther 25 (2003) 2647-2668
8. Ikeda U., Kanbe T., Nakayama I., Kawahara Y., Yokoyama M., and Shimada K. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1B. Eur J Pharmacol 290 (1995) 69-73
9. Muller J.E. Spironolactone in the management of congestive heart failure. Am J Cardiol 65 (1990) 51K-53K
10. MacFadyen R.J., Barr C.S., and Struthers A.D. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 35 (1996) 30-34
11. Ramires F.J.A., Mansur A., Coelho O., Marahnao M., Gruppi C.J., Mady C., et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. Am J Cardiol 85 (2000) 1207-1211
12. Zannad F., Alla F., Dousset B., Perez A., Pitt B., and on behalf of the RALES investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure. Circulation 102 (2000) 2700-2706
13. Lacolley P., Safar M.E., Lucet B., Ledudal K., Labat C., and Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 37 (2001) 662-667
14. Katz S.D., Biasucci L., Sabba C., Strom J.A., Jondeau G., Galvao M., et al. Impaired endothelium mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol 19 (1992) 918-925
15. Kubo S.H., Rector T.S., Bank A.J., Williams R.E., and Heifetz S.M. Endothelium dependent vasorelaxation is attenuated in patients with heart failure. Circulation 84 (1991) 1589-1596
16. Ontkean M., Gay R., and Greenberg B. Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure. Circ Res 69 (1991) 1088-1096
17. Drexler H., Hayoz D., Munzel T., Just H., Zelis R., and Brunner H.R. Endothelial function in congestive heart failure. Am Heart J 126 (1993) 761-764
18. 1 receptor blockade after myocardial infarct on myocardial fibrosis, stiffness, and contractility. Am J Physiol 276 (1999) H873-H880
19. 2 receptor. J Pharmacol Exp Therapeutics 307 (2003) 1171-1178
20. Barr C.S., Lang C.C., Hanson J., Arnott M., Kennedy N., and Struthers A.D. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 76 (1995) 1259-1265
21. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
22. Bauersachs J., Fraccarollo D., Ertl G., Gretz N., Wehling M., and Christ M. Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition. Circulation 102 (2000) 2325-2328
23. Tsutamoto T., Wada A., Maeda K., Mubuchi N., Hayashi M., Tsutsui T., et al. Effects of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 37 (2001) 1228-1233
24. Kinugawa T., Ogino K., Kato M., Furuse Y., Shimoyama M., Mori M., et al. Effects of spironolactone on exercise capacity and neurohormonal factors in patients with heart failure treated with loop diuretics and ACEI. Gen Pharmacol 31 (1998) 93-99
25. Korkmaz M.E., Muderrisoglu H., Ulucam M., and Ozin B. Effects of spironolactone on heart rate variability and left ventricular systolic function in severe ischemic heart failure. Am J Cardiol 86 (2000) 649-653
26. Furchgott R.F., and Zawadski V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 (1980) 373-376
27. Litwin S.E., Litwin C.M., Raya T.E., Warner A., and Goldman S. Contractility and stiffness of noninfarcted myocardium following coronary ligation in rats: Effects of chronic angiotensin converting enzyme inhibition. Circulation 83 (1991) 1028-1037
28. Gaballa M.A., and Goldman S. Overexpression of endothelium nitric oxide synthase reverses the diminished vasorelaxation in the rat hindlimb in heart failure. J Mol Cell Cardiol 31 (1999) 1243-1252
29. Katz S.D., Khan T., Zeballos G.A., Mathew L., Potharlanka P., Knecht M., et al. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation 99 (1999) 2113-2117
30. Agnoletti L., Curello S., Bacheti T., Malacarne F., Gaia G., Comini L., et al. Serum from patients with severe heart failure downregulates eNOS and its proapoptotic: Role of tumor necrosis factor-alpha. Circulation 100 (1999) 1983-1991
31. Clement D.L. Peripheral action of spironolactone: plethysmographic studies. Am J Cardiol 65 (1990) 12K-13K
32. Quashning T., Ruschitzka F., Shaw S., and Luscher T.F. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 37 (2001) 801-805
33. Lagrue G., Ansquer J.C., and Meyer-Heine A. Peripheral action of spironolactone: improvement in arterial elasticity. Am J Cardiol 65 (1990) 9K-11K
34. Schohn D.C., Jahn H.A., and Pelletier B.C. Dose related cardiovascular effects of spironolactone. Am J Cardiol 71 (1993) 40A-45A
35. Duprez D.A., De Buyzere M.L., Rietzschel E.R., Taes Y., Clement D.L., Morgan D., et al. Increase relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 19 (1998) 1371-1376
36. 2 conversion in patients with chronic heart failure. Circulation 101 (2000) 594-597
37. Heitzer T., Baldus S., van Kodolitsch Y., Rudolph V., and Meinertz T. Systemic endothelial dysfunction as an early predictor of adverse outcomes in heart failure. Arterioscler Thromb Vasc Biol 25 (2005) 1174-1179
38. Katz S.D., Hryniewicz K., Hrilijac I., Balidemaj K., Dimayuga C., Hudaihed A., et al. Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 111 (2005) 310-314
39. Jorde U.P., Vittorio T., Katz S.D., Colombo P.C., Latif F., and LeJemtel T.H. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 106 (2002) 1055-1057
40. Hirsch A.T., Talsness C.E., Schunkert H., Paul M., and Dzau V.J. Tissue-specific acativation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 69 (1991) 475-482
41. Hirsch A.T., Opsahl J.A., Lunzer M.M., and Katz A.S. Active renin and angiotensinogen in cardiac interstitial fluid after myocardial infarction. Am J Physiol 276 (2005) H1818-H1826
42. Silvestre J.-S., Heymes C., Oubenaissa A., Valerie R., Aupetit-Faisant B., Carayon A., et al. Activation of cardiac aldosterone production in rat myocardial infarction. Circulation 99 (1999) 2694-2701
43. Veldhuisen D.J., van Gilst W.H., de Smet B.J.G., de Graeff P.A., Scholtens E., Buikema H., et al. Neurohumoral and hemodynamic effects of ibopamine in a rat model of chronic myocardial infarction and heart failure. Cardiovasc Drugs Therapy 8 (1994) 245-250
44. Karram T., Abbasi A., Keidar S., Golomb E., Hochberg I., Winaver J., et al. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoform in rats with experimental heart failure. Am J Physiol 289 (2005) H1351-H1358
45. Vasan R.S., Evans J.C., Benjamin E.J., Levy D., Larson M.G., Sundstrom J., et al. Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension 43 (2004) 957-962
46. Swedberg K., Eneroth P., Kjekshus J., Wilhelmsen L., and for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82 (1990) 1730-1736